Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome

Maureen M. Jonas, Laura E. Krawczuk, Heung Bae Kim, Craig Lillehei, Antonio Perez‐Atayde – 22 December 2004 – Nonalcoholic fatty liver disease (NAFLD) has been reported in adults with hypothalamic or pituitary dysfunction, and some have progressed to end stage liver disease requiring transplantation. We report a teenager who intially presented with hypoxia due to intrapulmonary shunting, found to have NAFLD and cirrhosis associated with a hypothalamic tumor and panhypopituitarism. The NAFLD recurred very quickly after a successful liver transplant.

Abdominal compartment syndrome after liver transplantation

Alexander E. Handschin, Markus Weber, Eberhard Renner, Pierre‐Alain Clavien – 22 December 2004 – The abdominal compartment syndrome is a well‐known complication after abdominal trauma and is increasingly recognized as a potential risk factor for renal failure and mortality after adult orthotopic liver transplantation (OLT). We present a case report of a young patient who presented with acute liver failure complicated by an acute pancreatitis. The patient developed an acute abdominal compartment syndrome after OLT.

Epoetin alfa improves quality of life in anemic HCV‐infected patients receiving combination therapy

Paul J. Pockros, Mitchell L. Shiffman, Eugene R. Schiff, Mark S. Sulkowski, Zobair Younossi, Douglas T. Dieterich, Teresa L. Wright, Samir H. Mody, K. Linda Tang, Betty L. Goon, Peter J. Bowers, Gerhard Leitz, Nezam H. Afdhal, PROACTIVE Study Group – 24 November 2004 – Anemia and decreased health‐related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection.

PGE1‐induced NO reduces apoptosis by D‐galactosamine through attenuation of NF‐κB and NOS‐2 expression in rat hepatocytes

Emilio Siendones, Dalia Fouad, María José M. Díaz‐Guerra, Manuel de la Mata, Lisardo Boscá, Jordi Muntané – 24 November 2004 – Prostaglandin E1 (PGE1) reduces cell death in experimental and clinical liver dysfunction. We have previously shown that PGE1 preadministration protects against NO‐dependent cell death induced by D‐galactosamine (D‐GalN) through a rapid increase of nuclear factor κB (NF‐κB) activity, inducible NO synthase (NOS‐2) expression, and NO production.

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

Olav Dalgard, Kristian Bjøro, Kjell Block Hellum, Bjørn Myrvang, Ståle Ritland, Kjell Skaug, Nils Raknerud, Helge Bell – 24 November 2004 – The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR). In a noncontrolled multicenter trial, 122 treatment‐naive patients received 1.5 μg/kg pegylated interferon alfa‐2b subcutaneously once weekly and 800 to 1,400 mg/d ribavirin based on body weight.

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma

Margarita Sala, Josep M. Llovet, Ramon Vilana, Lluís Bianchi, Manel Solé, Carmen Ayuso, Concepció Brú, Jordi Bruix, for the Barcelona Cly'nic Liver Cancer (BCLC) Group – 24 November 2004 – Outcome predictors in patients with hepatocellular carcinoma (HCC) who are treated with percutaneous ablation are ill defined, and it is unknown if successful therapy is associated with improved survival. In our study, 282 cirrhotic patients with early nonsurgical HCC were treated with percutaneous ablation during a 15‐year period.

Subscribe to